PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15728660-0 2005 Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 21-26 15728660-0 2005 Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 132-137 15728660-7 2005 Simvastatin reduced TPA- and PDGF/IL-1-induced MMP-9 secretion and mRNA levels, effects reversed by geranylgeranyl pyrophosphate and mimicked by inhibiting Rho geranylgeranylation or Rho-kinase (ROCK). Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 47-52 15728660-11 2005 Together these data suggest that simvastatin reduces MMP-9 secretion from human SV-SMC by inhibiting the RhoA/ROCK pathway and decreasing MMP-9 mRNA levels independently of effects on signaling pathways required for MMP-9 gene expression. Simvastatin 33-44 matrix metallopeptidase 9 Homo sapiens 53-58 15728660-11 2005 Together these data suggest that simvastatin reduces MMP-9 secretion from human SV-SMC by inhibiting the RhoA/ROCK pathway and decreasing MMP-9 mRNA levels independently of effects on signaling pathways required for MMP-9 gene expression. Simvastatin 33-44 matrix metallopeptidase 9 Homo sapiens 138-143 15728660-11 2005 Together these data suggest that simvastatin reduces MMP-9 secretion from human SV-SMC by inhibiting the RhoA/ROCK pathway and decreasing MMP-9 mRNA levels independently of effects on signaling pathways required for MMP-9 gene expression. Simvastatin 33-44 matrix metallopeptidase 9 Homo sapiens 138-143 15537504-0 2004 Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Simvastatin 122-133 matrix metallopeptidase 9 Homo sapiens 91-96 15537504-11 2004 Simvastatin (0.1-10 mumol/l) concentration dependently inhibited TNFalpha-induced myofibroblast proliferation, invasion and MMP-9 secretion. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 124-129 15537504-12 2004 CONCLUSIONS: TNFalpha, acting predominantly via the TNF-R1 receptor, increased human atrial myofibroblast proliferation, invasion and MMP-9 secretion, all of which were inhibited by simvastatin. Simvastatin 182-193 matrix metallopeptidase 9 Homo sapiens 134-139 15458690-6 2004 Simvastatin significantly reduced plasma levels of total MMP-9 and TIMP-1 more (P=0.005 and P=0.036, respectively), compared with fenofibrate showing no reduction. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 57-62 15210533-9 2004 In contrast, simvastatin enhanced the proteolytic capacity of MMP-2 and MMP-9, with a statistically significant increase of MMP-2 activity when compared with findings in controls. Simvastatin 13-24 matrix metallopeptidase 9 Homo sapiens 72-77 15210533-11 2004 CONCLUSIONS: Interferon beta exhibits inhibitory effects at the posttranslational level of MMP activity, whereas simvastatin augments the proteolytic activity of MMP-2 and MMP-9, suggesting that statins exert anti-inflammatory and proinflammatory effects. Simvastatin 113-124 matrix metallopeptidase 9 Homo sapiens 172-177 15706857-5 2004 Like Simvastatin AS and PNS had the function of reducing MMP-9 and accommodating lipid metabolism. Simvastatin 5-16 matrix metallopeptidase 9 Homo sapiens 57-62 15107580-0 2004 Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 71-97 15107580-3 2004 In this study, we proposed that simvastatin reduces MMP-9 expression in osteoblasts and HT1080 fibrosarcoma cell line. Simvastatin 32-43 matrix metallopeptidase 9 Homo sapiens 52-57 15107580-5 2004 The results from gelatin zymography and Western blot analysis revealed that simvastatin suppressed MMP-9 activity in these cells in concentration- and time-dependent manners. Simvastatin 76-87 matrix metallopeptidase 9 Homo sapiens 99-104 15107580-7 2004 Collectively, these results suggest that simvastatin is a potent drug for inhibition of MMP-9 expression in osteoblastic cells and HT1080 fibrosarcoma cells. Simvastatin 41-52 matrix metallopeptidase 9 Homo sapiens 88-93 12023838-6 2002 Here we report that neointima formation in organ-cultured human SV segments is inhibited by simvastatin, an effect that is associated with reduced MMP-9 activity. Simvastatin 92-103 matrix metallopeptidase 9 Homo sapiens 147-152 12659988-5 2003 Compared with pretreatment values, simvastatin significantly lowered plasma levels of MMP-9, TF, and PAI-1 (P=0.009, P=0.032, and P=0.007, respectively). Simvastatin 35-46 matrix metallopeptidase 9 Homo sapiens 86-91 12659988-6 2003 There were significant inverse correlations between pretreatment MMP-9, TF activity or PAI-1 antigen and the degree of change in those levels after simvastatin (r=-0.793, P<0.001; r=-0.482, P=0.005 and r=-0.590, P<0.001, respectively). Simvastatin 148-159 matrix metallopeptidase 9 Homo sapiens 65-70 12096273-9 2002 RESULTS: Simvastatin dose dependently reduced neointima formation (P =.004) in association with reduced MMP-9 activity (P =.03). Simvastatin 9-20 matrix metallopeptidase 9 Homo sapiens 104-109 11428539-6 2001 Administration of simvastatin significantly lowered plasma levels of matrix metalloproteinase-9 (MMP-9) and monocyte chemoattractant protein-I [33+/-46 and 13+/-19%, respectively (P = 0.027 and 0.020, respectively)]. Simvastatin 18-29 matrix metallopeptidase 9 Homo sapiens 69-95 11428539-6 2001 Administration of simvastatin significantly lowered plasma levels of matrix metalloproteinase-9 (MMP-9) and monocyte chemoattractant protein-I [33+/-46 and 13+/-19%, respectively (P = 0.027 and 0.020, respectively)]. Simvastatin 18-29 matrix metallopeptidase 9 Homo sapiens 97-102 11428539-8 2001 There were significant inverse correlations between pretreatment levels of MMP-9 and the degree of change in those levels after administration of simvastatin (r = -0.714, P= 0.005). Simvastatin 146-157 matrix metallopeptidase 9 Homo sapiens 75-80 32173476-5 2020 Our study was aimed at testing the effect of three different drugs (pioglitazone, doxycycline, simvastatin) on MMP-9 and PPAR-gamma expression in AAA-MSCs. Simvastatin 95-106 matrix metallopeptidase 9 Homo sapiens 111-116 34680049-7 2021 As a result of EAM, there was an enhanced activation of MMP-9, which was significantly reduced in the high-dose simvastatin group compared to the low-dose group. Simvastatin 112-123 matrix metallopeptidase 9 Homo sapiens 56-61 34680049-9 2021 CONCLUSIONS: The cardioprotective effects of simvastatin in the acute phase of EAM are, at least in part, due to its ability to decrease MMP-9 activity and subsequent decline in myofilaments degradation and suppression of inflammation. Simvastatin 45-56 matrix metallopeptidase 9 Homo sapiens 137-142 33250768-7 2020 Both siRNA-mediated knockdown of PTTG1 expression and simvastatin treatment markedly inhibited MDA-MB-231 cell invasion, MMP-2 and MMP-9 activity, and the expression of PTTG1 downstream target genes, while ectopic expression of PTTG1 promoted cancer cell invasion, and partly reversed simvastatin-mediated inhibition of cell invasion. Simvastatin 54-65 matrix metallopeptidase 9 Homo sapiens 131-136 32173476-11 2020 Interestingly, MMP-9 mRNA resulted significantly decreased after each treatment, recording a down-regulation of 50% in presence of pioglitazone, 90% with doxycycline and 40% with exposed to simvastatin, in comparison to untreated cells. Simvastatin 190-201 matrix metallopeptidase 9 Homo sapiens 15-20 32173476-13 2020 CONCLUSIONS: Our data support the potential therapeutic effect of pioglitazone, doxycycline and simvastatin on AAA by reducing the MMP-9 expression in a patient-specific model (AAA-MSCs). Simvastatin 96-107 matrix metallopeptidase 9 Homo sapiens 131-136 25704622-8 2015 Pre-treatment with simvastatin (S-L) reduced IL-6 (P = 0.02), TNF-alpha (P = 0.02), and MMP-9 (P = 0.01); post-treatment (L-S) reduced IL-1beta (P = 0.02) and TNF-alpha (P = 0.04), while simultaneous treatment (L+S) did not reduce any of the cytokines tested. Simvastatin 19-30 matrix metallopeptidase 9 Homo sapiens 88-93 32421147-7 2020 Prior incubation with simvastatin, lovastatin, and atorvastatin inhibited TGF-beta2-mediated MMP-2 and MMP-9 expression and activities. Simvastatin 22-33 matrix metallopeptidase 9 Homo sapiens 103-108 31260663-8 2019 The results showed that simvastatin downregulated the degradation related genes MMP-3, MMP-13, MMP-2, MMP-9 and TIMP-2 in a dose-dependent manner. Simvastatin 24-35 matrix metallopeptidase 9 Homo sapiens 102-107 28390432-0 2017 Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease. Simvastatin 93-104 matrix metallopeptidase 9 Homo sapiens 10-36 28390432-2 2017 METHODS: We investigated the association of MMP9 rs3918242 single nucleotide polymorphism with inflammation and lipid-lowering efficacy after simvastatin treatment in Chinese patients with CHD. Simvastatin 142-153 matrix metallopeptidase 9 Homo sapiens 44-48 28390432-9 2017 CONCLUSIONS: MMP9 rs3918242 TT genotype is associated with elevated serum TG and LDL-C, and enhanced LDL-C-lowering response upon simvastatin treatment in Chinese patients with CHD. Simvastatin 130-141 matrix metallopeptidase 9 Homo sapiens 13-17 26988924-4 2016 RESULTS: The in vitro studies showed that simvastatin potently inhibited the expression of MMP-1, MMP-8, and MMP-9 upregulated by lipopolysaccharide (LPS) and high glucose in mononuclear cells. Simvastatin 42-53 matrix metallopeptidase 9 Homo sapiens 109-114 25993292-5 2015 Simvastatin, as well as pitavastatin significantly reduced the secretion of matrix metalloproteinase (MMP)-9, monocyte chemoattractant protein (MCP)-2 and epithelial neutrophil-activating peptide (CXCL5) under both basal and TNF-alpha-stimulated conditions. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 76-108 25993292-7 2015 Moreover, the effect of simvastatin and the JNK inhibitor SP600125 was additive in inhibiting the secretion of MMP-9, MCP-2 and CXCL5. Simvastatin 24-35 matrix metallopeptidase 9 Homo sapiens 111-116 25800096-7 2015 Moreover, a significant increase in MMP9/TIMP2 complex concentration in ILTs of patients on simvastatin was noted (median 94.71 ng/mL in the simvastatin group vs. 36.80 ng/mL in the non-statin group; p = .01). Simvastatin 92-103 matrix metallopeptidase 9 Homo sapiens 36-40 25800096-7 2015 Moreover, a significant increase in MMP9/TIMP2 complex concentration in ILTs of patients on simvastatin was noted (median 94.71 ng/mL in the simvastatin group vs. 36.80 ng/mL in the non-statin group; p = .01). Simvastatin 141-152 matrix metallopeptidase 9 Homo sapiens 36-40 24506800-9 2014 Moreover, the levels of MMP-9 and TGF-beta1, factors involved in the breakdown of basement membrane and fibroproliferation, were lower in patients with PDR having simvastatin medication. Simvastatin 163-174 matrix metallopeptidase 9 Homo sapiens 24-29 25316568-0 2014 Simvastatin induces NFkappaB/p65 down-regulation and JNK1/c-Jun/ATF-2 activation, leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 93-119 25316568-0 2014 Simvastatin induces NFkappaB/p65 down-regulation and JNK1/c-Jun/ATF-2 activation, leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 121-126 25316568-1 2014 The aim of the present study was to explore the signaling pathways associated with the effect of simvastatin on matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia K562 cells. Simvastatin 97-108 matrix metallopeptidase 9 Homo sapiens 147-152 25316568-2 2014 In sharp contrast to its insignificant effect on MMP-2, simvastatin down-regulated MMP-9 protein expression and mRNA levels in K562 cells. Simvastatin 56-67 matrix metallopeptidase 9 Homo sapiens 83-88 25316568-5 2014 Over-expression of Pin1 suppressed simvastatin-induced MMP-9 down-regulation. Simvastatin 35-46 matrix metallopeptidase 9 Homo sapiens 55-60 25316568-11 2014 Simvastatin treatment also suppressed MMP-9 but not MMP-2 expression in human leukemia U937 and KU812 cells. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 38-43 25316568-12 2014 Taken together, our data indicate that simvastatin-induced p65 instability leads to MMP-9 down-regulation in leukemia cells, while simvastatin-induced JNK1/c-Jun/ATF-2 activation maintains the MMP-2 expression underlying p65 down-regulation. Simvastatin 39-50 matrix metallopeptidase 9 Homo sapiens 84-89 25432084-8 2014 Furthermore, simvastatin decreased H2O2-mediated induction of the cellular expression of MMP-2 and MMP-9, as well as of several components of the signaling complex activated by innate immune responses, including MyD88, TRAF2, TRAF6 and TRADD. Simvastatin 13-24 matrix metallopeptidase 9 Homo sapiens 99-104 23913656-0 2013 Simvastatin therapy decreases MMP-9 levels in obese women. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 30-35 24233024-6 2014 Simvastatin suppressed the proliferation of gastric cancer cells, enhanced the apoptotic effects of capecitabine, suppressed the constitutive activation of NF-kappaB, and abrogated the expression of cyclooxygenase-2 (COX-2), cyclin D1, Bcl-2, survivin, CXC motif receptor 4, and MMP-9 proteins. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 253-284 24233024-8 2014 As compared to the vehicle control, simvastatin also suppressed the expression of NF-kappaB-regulated gene products such as cyclin D1, COX-2, ICAM-1, MMP-9, survivin, Bcl-xL, and XIAP in tumor tissues. Simvastatin 36-47 matrix metallopeptidase 9 Homo sapiens 150-155 24684779-7 2014 RESULTS: Simvastatin significantly reduced plasma interleukin-6, leptin, resistin and monocyte chemoattractant protein-1 (p < 0.001 for all); pioglitazone reduced interleukin-6, tumoral necrose factor-alpha, resistin and matrix metalloproteinase-9 (p < 0.001 for all). Simvastatin 9-20 matrix metallopeptidase 9 Homo sapiens 224-250 23913656-6 2013 Treatment with simvastatin significantly reduced MMP-9 levels and the MMP-9/TIMP-1 ratio (P < .05) when compared to the placebo group (P > .05). Simvastatin 15-26 matrix metallopeptidase 9 Homo sapiens 49-54 23913656-6 2013 Treatment with simvastatin significantly reduced MMP-9 levels and the MMP-9/TIMP-1 ratio (P < .05) when compared to the placebo group (P > .05). Simvastatin 15-26 matrix metallopeptidase 9 Homo sapiens 70-75 23913656-9 2013 These findings may have clinical importance since simvastatin therapy reduced cardiovascular risk and MMP-9 levels in obese woman without comorbidities, indicating a potentially new therapeutic approach. Simvastatin 50-61 matrix metallopeptidase 9 Homo sapiens 102-107 19299917-3 2009 However, it remained uncertain how cigarette smoke induced MMP-9 and how simvastatin inhibited cigarette smoke-induced MMP-9 expression in alveolar macrophages (AMs), a major source of MMP-9 in the lungs of COPD patients. Simvastatin 73-84 matrix metallopeptidase 9 Homo sapiens 119-124 20946258-6 2012 RESULTS: Under high glucose conditions, simvastatin dose-dependently inhibited VSMC migration, decreased PI3K/Akt pathway activity, reduced c-Raf and Ras expression, increased RhoB but not RhoA, Rac1, and Cdc2 expression, dose-dependently inhibited MMP-2, but not MMP-9, activity, and dose-dependently inhibited NF-kappaB activity. Simvastatin 40-51 matrix metallopeptidase 9 Homo sapiens 264-269 19589242-5 2009 Serum levels of soluble OX40L and matrix metalloproteinase 9 levels were significantly reduced in patients with atherosclerotic cerebral infarction who were treated for 6 months with routine therapy plus simvastatin (n = 46) compared with patients receiving routine therapy alone (n = 30). Simvastatin 204-215 matrix metallopeptidase 9 Homo sapiens 34-60 23924855-7 2013 Importantly, simvastatin suppressed decreased MMP-9 protein expression and suppressed NF-kappaB activation in A549 cells. Simvastatin 13-24 matrix metallopeptidase 9 Homo sapiens 46-51 23924855-8 2013 Taken together, these results showed that the anticancer effect of simvastatin in lung cancer A549 cells via the inhibiting cell proliferation, influencing the cell cycle, downregulating cyclin D1 and CDKs expression, inducing apoptosis, and decreasing MMP-9 levels, possibly by inhibiting the activation of NF-kappaB. Simvastatin 67-78 matrix metallopeptidase 9 Homo sapiens 253-258 21448567-9 2011 Simvastatin and atorvastatin, but not pravastatin, decreased MMP-9/TIMP-1 ratio significantly (both P < 0.05), whereas atorvastatin and pravastatin, but not simvastatin, decreased MMP-2/TIMP-2 ratio significantly (both P < 0.05). Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 61-66 21448567-11 2011 Our results suggest that more lipophilic statins (simvastatin and atorvastatin), but not the hydrophilic statin pravastatin, downregulate net MMP-9 activity. Simvastatin 50-61 matrix metallopeptidase 9 Homo sapiens 142-147 19299917-3 2009 However, it remained uncertain how cigarette smoke induced MMP-9 and how simvastatin inhibited cigarette smoke-induced MMP-9 expression in alveolar macrophages (AMs), a major source of MMP-9 in the lungs of COPD patients. Simvastatin 73-84 matrix metallopeptidase 9 Homo sapiens 119-124 18326912-6 2008 The IMT and MMP-9 in the simvastatin treatment group and the control group were significantly higher than those in the normal control group (all P<0.05). Simvastatin 25-36 matrix metallopeptidase 9 Homo sapiens 12-17 18625914-2 2008 In this study, we reported that simvastatin, a 3-hydroxyl-3-methylglutaryl-CoA reductase inhibitor, effectively inhibited LPS-stimulated MMP-1 as well as MMP-8 and MMP-9 expression by U937 mononuclear cells. Simvastatin 32-43 matrix metallopeptidase 9 Homo sapiens 164-169 18326912-8 2008 Eight weeks after the simvastatin treatment, the serum MMP-9 levels decreased significantly(P<0.05). Simvastatin 22-33 matrix metallopeptidase 9 Homo sapiens 55-60 18326912-10 2008 The anti-atherosclerosis effect of simvastatin may partly attribute to its ability to lower the serum MMP-9. Simvastatin 35-46 matrix metallopeptidase 9 Homo sapiens 102-107 16386257-6 2006 In the presence or absence of E(2) (5 nM), simvastatin treatment in the range of 0.1-5.0 microM significantly reduced macrophage MMP-9 enzymatic activity (p<0.005) in a dose-dependent manner. Simvastatin 43-54 matrix metallopeptidase 9 Homo sapiens 129-134 17560598-0 2007 Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 88-93 17560598-2 2007 We have previously reported that simvastatin inhibits tumor necrosis factor-alpha (TNFalpha)-induced cardiac myofibroblast invasion and MMP-9 secretion, key events in this remodeling process. Simvastatin 33-44 matrix metallopeptidase 9 Homo sapiens 136-141 17560598-12 2007 In summary, simvastatin reduces TNFalpha-induced invasion of human cardiac myofibroblasts through two distinct mechanisms: (i) by attenuating cell migration via Rho-kinase inhibition and subsequent cytoskeletal disruption, and (ii) by decreasing MMP-9 secretion via a post-transcriptional mechanism. Simvastatin 12-23 matrix metallopeptidase 9 Homo sapiens 246-251 17574455-3 2007 Although recruitment closed early because of increasing statin use among eligible patients, with only 21 patients we demonstrated a 40% reduction in MMP-9 levels in the AAA wall in patients randomised to simvastatin. Simvastatin 204-215 matrix metallopeptidase 9 Homo sapiens 149-154 16386257-8 2006 These findings indicate that ANXII plays a central role in modulating the enzymatic activity of MMP-9 in response to E(2) and that E(2)-mediated ANXII expression and MMP-9 activity can be prevented by simvastatin. Simvastatin 201-212 matrix metallopeptidase 9 Homo sapiens 96-101 16386257-8 2006 These findings indicate that ANXII plays a central role in modulating the enzymatic activity of MMP-9 in response to E(2) and that E(2)-mediated ANXII expression and MMP-9 activity can be prevented by simvastatin. Simvastatin 201-212 matrix metallopeptidase 9 Homo sapiens 166-171 16386257-9 2006 Prevention of E(2)-mediated activation of MMP-9 by simvastatin suggests that concurrent statin use may account for early event risk of myocardial infarction seen with hormone therapy in recent clinical trials. Simvastatin 51-62 matrix metallopeptidase 9 Homo sapiens 42-47 17184595-0 2006 Simvastatin could prevent increase of the serum MMP-9/TIMP-1 ratio in acute ischaemic stroke. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 48-53 16741180-0 2006 Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Simvastatin 80-91 matrix metallopeptidase 9 Homo sapiens 50-76 16741180-6 2006 RESULTS: Simvastatin (1 to 10 micromol/L) significantly reduced tPA-induced MMP-9 in cortical astrocytes. Simvastatin 9-20 matrix metallopeptidase 9 Homo sapiens 76-81 17184595-2 2006 The aim of our study was to analyse both serum MMP-9 and its most specific endogenous inhibitor (TIMP-1) levels in AIS and to check whether HMG-CoA reductase inhibitor (simvastatin) affects the MMP-9/TIMP-1 ratio value. Simvastatin 169-180 matrix metallopeptidase 9 Homo sapiens 194-199 17184595-8 2006 These findings indicate that simvastatin given during 24 hours after the onset of stroke could have an influence on the MMP-9/TIMP-1 ratio during AIS. Simvastatin 29-40 matrix metallopeptidase 9 Homo sapiens 120-125 16465063-4 2005 Both simvastatin and pravastatin strikingly suppressed MMP-9 activity in ex vivo culture of varicose veins. Simvastatin 5-16 matrix metallopeptidase 9 Homo sapiens 55-60 16465063-5 2005 Simvastatin suppressed MMP-9 at both the mRNA and protein levels as well as at the urokinase-type plasminogen activator protein level, resulting in the dramatic suppression of MMP-9 activity induced by tumor necrosis factor-alpha. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 23-28 16465063-5 2005 Simvastatin suppressed MMP-9 at both the mRNA and protein levels as well as at the urokinase-type plasminogen activator protein level, resulting in the dramatic suppression of MMP-9 activity induced by tumor necrosis factor-alpha. Simvastatin 0-11 matrix metallopeptidase 9 Homo sapiens 176-181